» Articles » PMID: 31174538

Chronic Obstructive Pulmonary Disease Upper Airway Microbiota Alpha Diversity is Associated with Exacerbation Phenotype: a Case-control Observational Study

Overview
Journal Respir Res
Specialty Pulmonary Medicine
Date 2019 Jun 9
PMID 31174538
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chronic obstructive pulmonary disease (COPD) frequent exacerbators (FE) suffer increased morbidity and mortality compared to infrequent exacerbators (IE). The association between the oral and sputum microbiota and exacerbation phenotype is not well defined. The objective of this study was to determine key features that differentiate the oral and sputum microbiota of FEs from the microbiota of IEs during periods of clinical stability.

Methods: We recruited 11 FE and 11 IE who had not used antibiotics or systemic corticosteroids in the last 1 month. Subjects provided oral wash and sputum samples, which underwent 16S V4 MiSeq sequencing and qPCR of 16S rRNA. Data were analyzed using Dada2 and R.

Results: FE and IE were similar in terms of age, FEV percent predicted (FEV1pp), pack-years of tobacco exposure, and St. George's Respiratory Questionnaire score. 16S copy numbers were significantly greater in sputum vs. oral wash (p = 0.01), but phenotype was not associated with copy number. Shannon diversity was significantly greater in oral samples compared to sputum (p = 0.001), and IE samples were more diverse than FE samples (p < 0.001). Sputum samples from FE had more Haemophilus and Moraxella compared to IE sputum samples, due to dominance of these COPD-associated taxa in three FE sputum samples. Amplicon sequencing variant (ASV)-level analysis of sputum samples revealed one ASV (Actinomyces) was significantly more abundant in IE vs. FE sputum (p = 0.048, Wilcoxon rank-sum test), and this persisted after controlling for FEV1pp. Principal coordinate analysis using Bray-Curtis distance with PERMANOVA analyses demonstrated clustering by anatomic site, phenotype, inhaled corticosteroid use, current tobacco use, COPD severity, and last professional dental cleaning.

Conclusions: FE have less diverse oral and sputum microbiota than IE. Actinomyces was significantly more abundant in IE sputum than FE sputum. The oral and sputum microbiota of COPD subjects cluster based on multiple clinical factors, including exacerbation phenotype. Even during periods of clinical stability, the frequent exacerbator phenotype is associated with decreased alpha diversity, beta-diversity clustering, and changes in taxonomic abundance.

Citing Articles

Relationship between Respiratory Microbiome and Systemic Inflammatory Markers in COPD: A Pilot Study.

Casadevall C, Quero S, Millares L, Faner R, Cosio B, Peces-Barba G Int J Mol Sci. 2024; 25(15).

PMID: 39126034 PMC: 11313397. DOI: 10.3390/ijms25158467.


Meta-analysis of the human upper respiratory tract microbiome reveals robust taxonomic associations with health and disease.

Quinn-Bohmann N, Freixas-Coutin J, Seo J, Simmons R, Diener C, Gibbons S BMC Biol. 2024; 22(1):93.

PMID: 38654335 PMC: 11040984. DOI: 10.1186/s12915-024-01887-0.


Exploring the Role of Gut-Lung Interactions in COPD Pathogenesis: A Comprehensive Review on Microbiota Characteristics and Inflammation Modulation.

Cheng Z, Zhang J Chronic Obstr Pulm Dis. 2024; 11(3):311-325.

PMID: 38563747 PMC: 11216226. DOI: 10.15326/jcopdf.2023.0442.


Tobacco use, self-reported professional dental cleaning habits, and lung adenocarcinoma diagnosis are associated with bronchial and lung microbiome alpha diversity.

Pragman A, Hodgson S, Wu T, Zank A, Kelly R, Reilly C Respir Res. 2024; 25(1):130.

PMID: 38500160 PMC: 10949571. DOI: 10.1186/s12931-024-02750-0.


Sputum microbiome α-diversity is a key feature of the COPD frequent exacerbator phenotype.

Pragman A, Hodgson S, Wu T, Zank A, Reilly C, Wendt C ERJ Open Res. 2024; 10(1).

PMID: 38333651 PMC: 10851948. DOI: 10.1183/23120541.00595-2023.


References
1.
Sullivan S, Ramsey S, Lee T . The economic burden of COPD. Chest. 2000; 117(2 Suppl):5S-9S. DOI: 10.1378/chest.117.2_suppl.5s. View

2.
Sethi S, Murphy T . Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev. 2001; 14(2):336-63. PMC: 88978. DOI: 10.1128/CMR.14.2.336-363.2001. View

3.
Kanner R, Anthonisen N, Connett J . Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001; 164(3):358-64. DOI: 10.1164/ajrccm.164.3.2010017. View

4.
Sethi S, Evans N, Grant B, Murphy T . New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002; 347(7):465-71. DOI: 10.1056/NEJMoa012561. View

5.
Spencer S, Jones P . Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003; 58(7):589-93. PMC: 1746751. DOI: 10.1136/thorax.58.7.589. View